SN
Syndax Pharmaceuticals, Inc.
SNDX · NASDAQ
$17.62 -0.11% (-$0.02)
1M -9.96%
Market Cap $1.56B
P/E Ratio -
Div. Yield -
ROE 372.94%
Piotroski F-Score Weak
3/9Valuation
12 /100
Expensive P/B 103.41x
P/S 6.20x
P/FFO N/A
Growth
0 /100
Declining Book val. growth 48.29%
FCF growth N/A
EPS growth N/A
Profitability
20 /100
Weak Op. margin 77.05%
Gross margin 97.47%
FCF margin 87.64%
Quality
5 /100
Poor ROA 31.37%
ROIC 32.12%
Asset turnover 0.36x
Debt
23 /100
High Int. coverage -1.58x
Debt/Equity 39.03x
Current ratio 6.77x
Stability
54 /100
Moderate Profitable years 0
Beta 0.37x
EPS volatility 20.28%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SNDX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael A. Metzger
Employees
298
Headquarters
New York City
Upcoming events
02 NOV
Earnings
Upcoming earnings report